Skip to content
10-Q

Quarterly Report

TransMedics Group, Inc. TMDX

0000950170-25-067004

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 33.83M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $55.6M
Current Liabilities Q1 2025 · Dec 31, 2024 $59.91M
Total Liabilities Q1 2025 · Mar 31, 2025 $571.22M
Total Liabilities Q1 2025 · Dec 31, 2024 $575.47M
Current Assets Q1 2025 · Mar 31, 2025 $505.92M
Current Assets Q1 2025 · Dec 31, 2024 $497.22M
Total Assets Q1 2025 · Mar 31, 2025 $837.53M
Total Assets Q1 2025 · Dec 31, 2024 $804.08M
Shares Diluted Q1 2025 · Mar 31, 2024 34.68M sh
Capex Q1 2025 · Mar 31, 2024 $44.17M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.44M
Stockholders Equity Q1 2025 · Mar 31, 2024 $159.47M
Stockholders Equity Q1 2025 · Dec 31, 2023 $137.2M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.35
Eps Basic Q1 2025 · Mar 31, 2024 $0.37
Sga Expense Q1 2025 · Mar 31, 2024 $36.16M
Rd Expense Q1 2025 · Mar 31, 2024 $11.38M
Net Income Q1 2025 · Mar 31, 2024 $12.2M
Operating Income Q1 2025 · Mar 31, 2024 $12.42M
Gross Profit Q1 2025 · Mar 31, 2024 $59.96M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $36.89M